Terms: = Breast cancer AND CD79B, ENSG00000007312, 974, P40259, IGB, B29 AND Clinical Outcome
3 results:
1. Tumor-dose-rate variations during robotic radiosurgery of oligo and multiple brain metastases.
Wilhelm ML; Chan MKH; Abel B; Cremers F; Siebert FA; Wurster S; Krug D; Wolff R; Dunst J; Hildebrandt G; Schweikard A; Rades D; Ernst F; Blanck O
Strahlenther Onkol; 2021 Jul; 197(7):581-591. PubMed ID: 32588102
[TBL] [Abstract] [Full Text] [Related]
2. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic breast cancer: A Randomized clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract] [Full Text] [Related]
3. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
[TBL] [Abstract] [Full Text] [Related]
